Form 4 for SOPH SOPHiA GENETICS SA
Accepted 2026-08-21 16:02:04 ET · period of report 2026-08-19 · accession 0001840706-26-000293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-21 16:02 | 2026-08-19 | SOPH | Valente Manuela | CHRO | M - OptEx | $3.20 | +10.0K | 220.4K | +5% | +$32.0K |
| DT | 2026-08-21 16:02 | 2026-08-19 | SOPH | Valente Manuela | CHRO | S - Sale+OE | $7.94 | -10.0K | 210.4K | -5% | -$79.4K |
| DT | 2026-08-21 16:02 | 2026-08-19 | SOPH | Valente Manuela | CHRO | M - OptEx | $0.00 | -10.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-08-19 | M | A | 10,000 | $3.20 | 220,450 | D | — | — | (F1) Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). |
| 2 | Common | Ordinary Shares | 2026-08-19 | S | D | 10,000 | $7.94 | 210,450 | D | — | — | (F1) Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Share Option (Right to Buy) | 2026-08-19 | M | D | 10,000 | $0.00 | 0 | D | $3.20 · — to 2029-01-01 | 10,000 Ordinary Shares | (F1) Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). (F3) The share options are fully vested and exercisable. (F4) Following the transaction reported on this line, the Reporting Person holds an aggregate total of 554, 276 derivative share options across all remaining grant tranches with varying exercise prices. |